Overview
Seattle Cancer Care Alliance provides comprehensive, leading-edge treatment for people diagnosed with multiple myeloma. Right now there are about 50,000 people in the United States who have multiple myeloma, also known as myeloma, a form of cancer that affects white blood cells called plasma cells. SCCA was formed, in part, to bring promising new treatments to patients faster. This means that people who have myeloma will find more treatment options at SCCA than might be found elsewhere, including participation in one of the clinical trials conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine.
If your condition requires a bone-marrow transplant, you should know that the Fred Hutchinson Transplant program at SCCA was ranked first in outcomes in a four-year study by the National Marrow Donor Program (NMDP) that measured one-year survival rates of patients among 122 transplant centers in the United States. The Hutchinson Center pioneered the use of bone-marrow transplants as a treatment for blood diseases over 40 years ago. Since then many patients with multiple myeloma have come from around the world to receive bone-marrow transplants at SCCA. Bone-marrow transplants have transformed multiple myeloma and related cancers, once thought incurable, into highly treatable diseases with survival rates as high as 80 percent.
